title: Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
abstract: BACKGROUND
  Postoperative atrial fibrillation (AF) following cardiac surgery is associated with an increased risk of stroke, prolonged hospitalization, and increased costs. Statin therapy is associated with a lower incidence of postoperative AF. We aimed to compare the preventive effects of rosuvastatin and atorvastatin on postoperative AF.
  
  
  METHODS
  This study included 168 patients undergoing elective cardiac surgery with cardiopulmonary bypass. Patients were divided into 2 groups according to treatment of statin. Group 1 (n = 96) was patients receiving atorvastatin, and group 2 (n = 72) was patients receiving rosuvastatin. Postoperative electrocardiographs (ECGs) and telemetry strips were examined for AF within postoperative period during hospitalization.
  
  
  RESULTS
  The incidences of postoperative AF were 17.9% (n = 17) in group 1 and 22.2% (n = 16) in group 2 (P = .48). Left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were not different between groups. Incidence of diabetes, hypertension, hyperlipidemia, smoking, myocardial infarction in past medical history, family history of atherosclerosis, male sex, drug use, and perioperative features were similar between groups.
  
  
  CONCLUSIONS
  The present study revealed that preoperative rosuvastatin or atorvastatin treatment did not have a different effect in preventing postoperative AF.
authors.affiliation: Department of Cardiology, Cardiology Institute of Istanbul University, Istanbul 34096, Turkey. drokayabaci@hotmail.com
authors.forename: Okay
authors.initials: O
authors.lastname: Abaci
authors.forename: Cuneyt
authors.initials: C
authors.lastname: Kocas
authors.forename: Veysel
authors.initials: V
authors.lastname: Oktay
authors.forename: Cenk Eray
authors.initials: CE
authors.lastname: Yildiz
authors.forename: Kadriye Orta
authors.initials: KO
authors.lastname: Kilickesmez
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yildiz
authors.forename: Zerrin
authors.initials: Z
authors.lastname: Yigit
mesh_terms: D000069059:Atorvastatin; D001281:Atrial Fibrillation / Q000453:epidemiology* / Q000517:prevention & control*; D015897:Comorbidity; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data*; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000601:surgery*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011292:Premedication; D015995:Prevalence; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D012189:Retrospective Studies; D018570:Risk Assessment; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin